Why Mannkind Is Here To Stay - Excellent Article

[hawaiiguy42]

A must read: www.aomarkets.com/mannkind-mnkd-stock-gains-market-falls-heres/

MannKind has had an incredibly rough time over the past year. So, it wouldn’t be expected to be one of the few stocks in the green when global markets are in the red. Nonetheless, that’s exactly what we saw on Friday. While the global market saw massive declines as the result of a Brexit vote, MNKD actually found its way to the green. The reason is simple. It actually revolves around the reason for the declines in the first place. Today, we’ll talk about why the company has had such a hard time in the market, why we’re seeing gains now, even through rough market conditions, and what we can expect to see from the stock moving forward.
Why MNKD Has Had Such A Rough Time

Over the past year, MannKind has given up a massive amount of its value because Afrezza sales didn’t go as planned. Afrezza is an insulin designed to be inhaled rather than injected. Considering the massive amount of people that are afraid of needles, the implications for the pediatric industry, and the amount of people that don’t have access to public restrooms when working, this should have flew off of the shelves. Nonetheless, that’s not what happened.

Shortly after announcing the FDA approval of Afrezza, MNKD contracted with Sanofi for the commercialization of the treatment. The only problem is that Sanofi was a direct competitor. If they did commercialize Afrezza properly, they’d likely lose money on the sale of their own product. As a result, commercialization moved at a snail’s pace. Sales just weren’t what investors wanted to see. Investors saw Afrezza as a failure, and sent MNKD tumbling downward.
Why The Stock Is Gaining

While MannKind has had a rough time in the market over the past year, the company is seeing gains at the moment. So, what’s the deal? Well, it all circles back to Afrezza.

MNKD announced that it would be starting the second launch of Afrezza in July. This is incredibly big news as the company now has a second chance to succeed. This time, things are quite a bit different too.

This launch is coming from MNKD directly as the company canceled its agreement with Sanofi earlier this year. Not to mention, over the year, the company has compiled massive amounts of data surrounding Afrezza. This data will help the company to commercialize the treatment better thanks to better presentations for physicians and patients.

On top of that MannKind has announced a partnership with JDRF. JDRF is a non-profit organization that is working to make lives better for those in the diabetic community. The partnership largely surrounds shaping Afrezza as a perfect option for the pediatric diabetic population. Afrezza is a much needed treatment in this area, and if done properly, could lead to massive profits.
What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from MNKD. In the short run, things are very uncertain. With global economic conditions being called into question, markets are struggling in a big way. I don’t see this coming to an end in the short run. After all, the Brexit is big news and will likely have massive economic and market implications.

With that said, I do see tremendous upside potential in MNKD in the long run. There’s a need for Afrezza in multiple markets surrounding the larger diabetes market. Now, it’s up to MannKind to reach out to these markets and sell the product. With their commercialization plan, I don’t see why they wouldn’t be able to do so.

What Do You Think?

[Deleted]

as a general rule. it doesnt matter what anyone thinks...the market always tell you the right thing - price

[sportsrancho]

I think Mike is a magic man because good press about Afrezza is showing up all over! ( See thread, good post on YMB:-)

[Deleted]

Jun 25, 2016 19:59:50 GMT -5 sportsrancho said:

I think Mike is a magic man because good press about Afrezza is showing up all over! ( See thread, good post on YMB:-)

This ?

www.napsnet.com/articles/72019.html

It was a blog by the Dr.
I think Mike is doing ok , but please dont credit everything to him.
There were news clips even before he came into picture.

[sportsrancho]

Jun 25, 2016 20:11:31 GMT -5 @iam2sekc4u2002 said:

Jun 25, 2016 19:59:50 GMT -5 sportsrancho said:

I think Mike is a magic man because good press about Afrezza is showing up all over! ( See thread, good post on YMB:-)

This ?

www.napsnet.com/articles/72019.html

It was a blog by the Dr.
I think Mike is doing ok , but please dont credit everything to him.
There were news clips even before he came into picture.

[ 10users liked this postsusers disliked this posts0Reply
Afrezza in my local newspaper
by my_taxes_are_2_high • 2 hours 47 minutes ago
Have not been to the MNKD msg board in a while, though I still own a ton (difficult to see your investment down 80% from it's peak) . Anyway, some excitement this morning...

Search "Innovations In Diabetes Care Bring Patients More Control"

I live in a very small coastal town in Oregon. I bought the local newspaper this morning (only comes out two days per week) and started reading it.To my surprise there is a 1/3 page article about AFREZZA written by Dr. Jean L. Selam, the CEO of the Diabetes Research Center in California. After reading, I searched for it online and found it was originally published in his blog and several research sites on May 6, 2016.

Anyway, was surprised to see something about AFREZZA locally. Curious as to whether or not others are seeing this show up locally too? Interesting as if this is happening around the country, seems like part of the grassroots marketing strategy.

Read more: mnkd.proboards.com/thread/5433/good-post-ymb#ixzz4Ce11dWKw

[mannmade]

Dr. Selem is a big believer in AFREZZA. He also knew Al.

[mnholdem]

Jun 25, 2016 19:59:50 GMT -5 sportsrancho said:

I think Mike is a magic man because good press about Afrezza is showing up all over! ( See thread, good post on YMB:-)

If you Google "Afrezza" and filter your search for just the past 24 hours, you will discover that there have been reprints of Castagna's interview with Nate Pile that was published in Forbes. I counted more than one hundred news outlets that have reprinted the Forbes article in the past two days. The author wrote that Castagna contacted him to share the Pile interview, which he (Kam) submitted to Forbes as a contributing author. Say what you want about Castagna, but he definitely has demonstrated his experience of how (and where) to get news published about Afrezza.

[cm5]

Reposting thekindaguyiyam's find below: May 5, 2016 21:48:43 GMT -4 cm5  Mannkind: A Growing Threat To The Status Quo

Read more: mnkd.proboards.com/post/68411/quote/5445#ixzz4CeOoox5v

The countdown to lift off is accelerating----
4 hours ago thekindaguyiyam said:

Mountain Grove News Journal: Wednesday, May 4, 2016 6:44 am | Updated: 2:30 am, Thu May 5, 2016.
by Jean Louis Selam, M.D.

(NAPSI)—According to the American Diabetes Association, at least a third of Americans will develop the condition at some time in their lives. It can’t be cured but it can be managed.

While medicine has improved the quality of life of people with diabetes significantly over the years, the need for some way to regulate blood sugar remains unchanged. Researchers are exploring new pathways to innovative treatments. For instance, one research team identified a new link between heart hormones, insulin resistance and obesity, which could signal new treatment options for those with type 2 diabetes.

Continued insights into the medical characteristics of the main groups of people with diabetes have unveiled some new methods that doctors can use to correctly identify forms of diabetes sooner. Armed with these, doctors can proactively and more effectively treat once-rare variations of this condition.

One new treatment is an inhalable form of insulin that acts quickly, so users have greater flexibility in managing blood glucose fluctuations that often occur after eating.

This means more spontaneity for people with diabetes. Injected insulin usually needs to be taken 20 to 30 minutes before eating and pills can take longer still. These proven medicines are very important to any diabetes care regimen but they’re not easily adjustable.

The inhalable treatment, called Afrezza, works for most people with type 1 and type 2 diabetes, and it may be especially helpful for many newly diagnosed adults with type 2 who aren’t aware of their options and may forgo treatment due to the overwhelming nature of the diagnosis. Such people should check with a doctor to see if this might help.

It offers three advantages for adults with type 2 diabetes:

1. Few to no injections. Not everyone with type 2 diabetes needs insulin injections, but for those who do, this can lower or eliminate the need.

2. Less paraphernalia. People with diabetes don’t just carry around a vial of insulin; there are syringes, swabs for cleaning injection sites, and more. Many people ration these supplies to make sure the quantities covered by their health care plans will last. This is especially important as the estimated medical costs for people with diabetes are twice as high as for people without diabetes. With a supplemental insulin in the discreet form of an inhaler, people with diabetes can leave more supplies at home and still feel prepared for whatever may come their way.

3. Faster peak action time and shorter duration. Social occasions are often reduced to a game of “unit roulette” for many people with diabetes. With little control over how quickly a restaurant order will arrive or what food will be at a cocktail party, people may find their choices limited, and end up with either too much or too little insulin in their systems. This supplemental treatment bridges the gap between a regular regimen and those special occasions.

All this can give people a sense of control over their condition. Diabetes needn’t be the definition of who a person is. You can live your life fully prepared for the unexpected and in control.

Learn More
For further facts, visit www.afrezza.com.
• Dr. Selam is CEO of the Diabetes Research Center in California and author of several articles on insulin therapy techniques. He has also performed pioneer work on intraperitoneal insulin and insulin-induced remissions.

On the Net:North American Precis Syndicate, Inc.(NAPSI)
www.news-journal.net/online_features/health_and_wellness/article_6fb6e9cd-05a8-583f-a4da-8382ed7d582c.html

"When an idea reaches critical mass there is no stopping the shift its presence will induce.
Marianne Williamson

[brotherm1]

Link to Dr. Selam's biography. Good read

www.uciinc.net/about.html

[Deleted]

Jun 25, 2016 19:46:33 GMT -5 @iam2sekc4u2002 said:

as a general rule. it doesnt matter what anyone thinks...the market always tell you the right thing - price

Then why are you on a MannKind message board?

[sportsrancho]

Jun 25, 2016 19:46:33 GMT -5 @iam2sekc4u2002 said:

as a general rule. it doesnt matter what anyone thinks...the market always tell you the right thing - price

As a general rule stocks only reflect their true value 30% of the time. The rest of the time they are either over valued or under valued.

[rvc]

Jun 25, 2016 19:37:32 GMT -5 hawaiiguy42 said:

A must read: www.aomarkets.com/mannkind-mnkd-stock-gains-market-falls-heres/

MannKind has had an incredibly rough time over the past year. So, it wouldn’t be expected to be one of the few stocks in the green when global markets are in the red. Nonetheless, that’s exactly what we saw on Friday. While the global market saw massive declines as the result of a Brexit vote, MNKD actually found its way to the green. The reason is simple. It actually revolves around the reason for the declines in the first place. Today, we’ll talk about why the company has had such a hard time in the market, why we’re seeing gains now, even through rough market conditions, and what we can expect to see from the stock moving forward.
Why MNKD Has Had Such A Rough Time

Over the past year, MannKind has given up a massive amount of its value because Afrezza sales didn’t go as planned. Afrezza is an insulin designed to be inhaled rather than injected. Considering the massive amount of people that are afraid of needles, the implications for the pediatric industry, and the amount of people that don’t have access to public restrooms when working, this should have flew off of the shelves. Nonetheless, that’s not what happened.

Shortly after announcing the FDA approval of Afrezza, MNKD contracted with Sanofi for the commercialization of the treatment. The only problem is that Sanofi was a direct competitor. If they did commercialize Afrezza properly, they’d likely lose money on the sale of their own product. As a result, commercialization moved at a snail’s pace. Sales just weren’t what investors wanted to see. Investors saw Afrezza as a failure, and sent MNKD tumbling downward.
Why The Stock Is Gaining

While MannKind has had a rough time in the market over the past year, the company is seeing gains at the moment. So, what’s the deal? Well, it all circles back to Afrezza.

MNKD announced that it would be starting the second launch of Afrezza in July. This is incredibly big news as the company now has a second chance to succeed. This time, things are quite a bit different too.

This launch is coming from MNKD directly as the company canceled its agreement with Sanofi earlier this year. Not to mention, over the year, the company has compiled massive amounts of data surrounding Afrezza. This data will help the company to commercialize the treatment better thanks to better presentations for physicians and patients.

On top of that MannKind has announced a partnership with JDRF. JDRF is a non-profit organization that is working to make lives better for those in the diabetic community. The partnership largely surrounds shaping Afrezza as a perfect option for the pediatric diabetic population. Afrezza is a much needed treatment in this area, and if done properly, could lead to massive profits.
What We Can Expect To See Moving Forward

Moving forward, I have a relatively mixed opinion of what we can expect to see from MNKD. In the short run, things are very uncertain. With global economic conditions being called into question, markets are struggling in a big way. I don’t see this coming to an end in the short run. After all, the Brexit is big news and will likely have massive economic and market implications.

With that said, I do see tremendous upside potential in MNKD in the long run. There’s a need for Afrezza in multiple markets surrounding the larger diabetes market. Now, it’s up to MannKind to reach out to these markets and sell the product. With their commercialization plan, I don’t see why they wouldn’t be able to do so.

What Do You Think?

[rvc]

The author is inaccurate on one very important point-MNKD did not cancel the contract with SNY- the opposite occurred. SNY canceled the contract with MNKD, and in fact, it blindsided MNKD management. To state it any differently, is misleading and false.